Cristina Guarducci, Research Scientist at Azienda USL Toscana Centro, Hospital of Prato, shared a post on LinkedIn:
“I’m really happy to share that our work, ‘ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance’ has just been published!
This study represents the main project of my postdoc at Dana-Farber Cancer Institute, and I am excited to finally share our findings.
In this paper, we show that:
- ESR1 mutations are enriched in clinical samples of acquired CDK4/6i resistance and can expand to near clonality;
- ESR1 Y537S measurably reshapes clonal and epigenetic evolution under palbociclib but has a weaker impact under abemaciclib;
- Palbociclib and abemaciclib impose distinct selective pressures leading to divergent resistant states with limited clonal overlap and asymmetric cross-resistance.
I would like to thank my PI, Rinath Jeselsohn, for her mentorship throughout this project, and all the co-authors and collaborators who made this work possible.
A special thank to all my colleagues from the Jeselsohn lab and the Brown lab at Dana-Farber Cancer Institute for making my postdoctoral journey so special. It has been a privilege to work in such an inspiring environment, surrounded by exceptional scientists and colleagues who became lifelong friends.”
Title: ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance
Authors: Cristina Guarducci, Daniel Abravanel, Douglas Russo, Kavya Prasad, Jingxin Fu, Zsuzsanna Nagy, Vishwajit Rao, Agostina Nardone, Yanan Kuang, Avery Feit, Wen Ma, Gabriella Cohen Feit, Francisco Hermida-Prado, Capucine Heraud, Miguel Munoz Gomez, Diana Elisa Garcia Cortes, Patrick Kurnia, Jorge Gomez Tejeda Zanudo, Rong Li, Xintao Qiu, Simona Cristea, Ariel Feiglin, Yu-Chen Cheng, Nancy U. Lin, Sara M. Tolaney, Luca Malorni, Piotr Sicinski, Kornelia Polyak, Cloud Paweletz, Henry Long, Chip Stewart, Franziska Michor, Gad Getz, Myles Brown, Rinath Jeselsohn
Other articles about Dana-Farber Cancer Institute on OncoDaily.